Targeted therapies for <i>KRAS</i>-mutant non-small lung cancer (NSCLC) have shown promising clinical results, however, incomplete tumoral responses and the inevitable emergence of therapeutic resistance remain critical challenges. Here, KRAS is linked to non-small cell lung carcinoma.